Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 September 2020 | Story Andre Damons | Photo Supplied
Dr Martin Nyaga, Senior Lecturer and Researcher: NGS, will be heading the World Health Organisation Collaborating Centre (WHO CC).

The University of the Free State (UFS) has been designated a World Health Organisation Collaborating Centre (WHO CC), and the university’s Next Generation Sequencing (NGS) Unit, in partnership with the World Health Organisation (WHO), will for the next four years be conducting genome sequencing of pathogenic organisms, including rotavirus strains from the African continent. 

This centre will be part of the Vaccine Preventable Diseases (VPD) Pathogens Genomics Cluster and will run from September 2020 to September 2024. 

Dr Martin Nyaga, Senior Lecturer and Researcher: NGS/Virology, who will be heading the WHO CC, says an institution is designated as a WHO CC by the WHO Director-General and endorsed by the host country’s minister of health to form part of an international collaborative network, carrying out activities in support of the WHO programmess at all levels. A designation as a WHO CC is a time-limited agreement of collaboration between WHO and the designated institution, through which the latter agrees to implement a series of concrete activities, specifically designed for WHO.

A supreme achievement

Says Dr Nyaga: “In my opinion, a WHO CC designation is one of the supreme achievements an institution can be conferred as a recognition for foregoing exceptional collaborative venture with the WHO and showing future potential to assist the WHO with its global programmes and in our case, the WHO Regional Office for Africa region to offer solutions to the WHO VPD Surveillance and pathogens genomics cluster.”

According to Dr Nyaga this designation was awarded to the UFS after the WHO was content with the outcome of a service contract whereby the UFS-NGS unit undertook a pilot rotavirus surveillance project at whole genome level, using two African countries for the pilot, Rwanda and Zambia.

“From the outcomes of the pilot surveillance project between 2017 and 2019, the WHO/AFRO was satisfied with the genomic data that was generated and partially disseminated in scientific databases and journals as a collaborative venture. 

“It was thus proposed to strengthen its existing collaboration with the UFS-NGS Unit, which initiated the application process to designate the UFS-NGS unit as a WHO CC, an initiative that has taken approximately 20 months to finalise through the different phases of the application and approvals for the designation,” explains Dr Nyaga.

The purpose of the WHO CC

The new WHO CC will upon request by the WHO, implement agreed work plans in a timely manner and to the highest possible standards of quality and must comply with the referred terms of reference and conditions. These include: 
• Conducting genome sequencing of pathogenic organisms causing VPD, including rotavirus strains collected as part of the routine VPD surveillance using NGS technology and analysis of the generated datasets using bioinformatics tools.

• Conducting molecular characterisation of specimens collected during outbreaks and public health emergencies as part of the support for monitoring, preparedness and response to VPD disease outbreaks in Africa.

• Provide technical guidance to WHO on strategies to improve laboratory molecular diagnostics, molecular typing and NGS of rotavirus diarrheal strains and other enteropathogens to detect novel and re-emerging strains. 

• Conduct validation of tools and new molecular diagnostics for detection and characterisation of unusual or rare VPD strains to guide studies and development of new vaccines for VPD.

• Organise capacity-building and training workshops on whole genome sequencing of priority VPD pathogenic organisms.

The impact of the WHO CC on the work of the UFS-NGS 

According to Dr Nyaga, the designation brings extra responsibilities to his work and to the activities of the UFS-NGS unit. “Such initiatives are very welcome to enhance the business aspects, research and academic activities of the UFS-NGS unit, as the benefits are quite holistic since the collaboration enhances co-ownership of data and offers opportunities to train postgraduate students and other scientists.

“It also expands the research infrastructure and most importantly contributes to policy for numerous African governments in important decisions such as vaccine implementation activities, from an informed point of view and managing public health needs that require rapid response like outbreaks that may lead to pandemics.” 
• The current WHO CC designations at South African Institutions of higher learning and research can be found at: 

News Archive

Researcher shares platform with Nobel Laureate at conference on nanomedicine
2013-01-10

Prof. Lodewyk Kock at the Everest viewpoint with Mount Everest behind him.
10 January 2013

Profs. Lodewyk Kock and Robert Bragg from the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS) both presented lectures at the first International Conference on Infectious Diseases and Nanomedicine that was held in Kathmandu, Nepal, late last year.

At the conference, also attended by senior representatives from the International Union of Microbiological Societies (IUMS), Prof. Kock delivered one of the two opening lectures, titled: Introducing New Nanotechnologies to Infectious Diseases (the other opening lecture was presented by Nobel Laureate, Prof. Barry J. Marshal). Prof. Kock also participated in the farewell address.

In two excellent lectures, Prof. Bragg spoke on Bacteriophages as potential treatment option of antibiotic-resistant bacteria, and on Bacterial resistance to quaternary ammonium compounds.

For Prof. Kock this very first conference on infectious diseases and nanomedicine was followed by a very exciting yeast research excursion through the Mount Everest Highway which winds through the villages of the Sherpa tribe.

He describes his journey: “The Mount Everest Highway is a rough road stretching through hills and glacial moraines of unfamiliar altitudes and cold temperatures. Throughout the journey I had to take care of not contracting altitude sickness which causes severe headaches and dizziness.

“The only way of transport is on foot, on long-haired cattle called Yaks, donkeys and by helicopter. After flying by plane from Kathmandu (the capital of Nepal), I landed at Lukla, regarded as the most dangerous airport in the world due to its short elevated runway and mountainous surroundings. From Lukla, the land of the Sherpa, I walked (trekked) with my Sherpa guide and porter (carrier) along the Everest Highway surrounded by various Buddhist Mani scripture stands, other Buddhist representations and many spectacular snow-tipped mountains of more than 6 000 m above sea level. Of these, the majestic mountain called Ama Dablam (6 812 m), the grand 8 516 m high peak of Lhotse and to its left the renowned Mount Everest at 8 848 m in height, caught my attention.

“Dwarfed by these mountain peaks on the horizon, I passed various villages until I eventually reached the beautiful village called Namche Bazar, the heart of the Khumbu region and hometown of the Sherpa. This took three days of up to six hours walking per day, while I spent the nights at the villages of Phakding and Monjo. From there I walked along the Dudh Kosi River which stretches towards Mount Everest, until I reached the high altitude Everest viewpoint – the end of my journey, after which I trekked back to Lukla to return to Kathmandu and South Africa.

“This expedition is the first exploration to determine the presence of yeasts in the Everest region. Results from this excursion will be used in collaborative projects with local universities in Nepal that are interested in yeast research.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept